

Fax*Lilly*

Eli Lilly and Company
Lilly Corporate Centre
Indianapolis, Indiana 46285
U.S.A.

RECEIVED
CENTRAL FAX CENTER

Date: 22 February 2006

FEB 22 2006

To: G. Chandra
Company: USPTO
Fax: 571-273-8300
Technology Center 1600

From: Greg Cox
Fax: 317-276-5172
Phone: 317-277-2620
Total Pages: 4

Privileged and Confidential Communication

RE: : 10/811,646
Docket No. : X-10822B
Group Art : 1646

CONFIDENTIALITY NOTICE: This fax message from Eli Lilly and Company (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply fax and destroy all copies of the original message.

Please contact Jan Fowler at 317-655-1715 if you incur any difficulties with this transmission.

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

FEB 22 2006

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

JANET FOWLER

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Suad Efendic)
Serial No. : 10/811,646)
Filed : March 29, 2004) Group Art Unit: 1646
For : Use of GLP-1 or Analogs in Treatment) Examiner: Chandra, G.
Of Myocardial Infarction)
Docket No. : X-10822B)

RESPONSE TO RESTRICTION AND/OR ELECTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Election Requirement was set forth in an Office Action mailed January 23, 2006, for the patent application captioned above.

Claims 1-12 were cancelled and new Claims 13-20 were added by Preliminary Amendment on Mar 29, 2004.

Claims are reproduced for the Examiner's convenience and begin on page 2 of this paper.
Remarks begin on page 3 of this paper.